Wednesday - April 08, 2026

Category Archives: Science

Ischemic Stroke Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

DelveInsight’s, “Ischemic Stroke Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Hearing Loss Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight

DelveInsight’s, “Hearing Loss Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Hearing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Heart Failure Clinical Trial Pipeline Accelerates as 70+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Heart Failure Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Heart Failure pipeline landscape. It covers the Heart Failure pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

IgA Nephropathy Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “IgA Nephropathy Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Living Forever – AI Reaches Founders Circle Capacity; Secures Infrastructure Support from ElevenLabs, AWS, Microsoft, and Google Cloud

Atlanta-based interactive family legacy platform backed by four leading technology providers as waitlist surges past 400 families ATLANTA – March 30, 2026 – Living Forever — AI, an Atlanta-based startup building the future of interactive family legacy technology, today announced it … Continue reading →

Pancreatic Cancer Treatment Pipeline Shows Strong Momentum as 170+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Pancreatic Cancer Pipeline Insight 2026” report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in Pthe ancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Thyroid Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 45+ Key Companies | DelveInsight

DelveInsight’s, “Thyroid Cancer Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

TGFB Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook

DelveInsight’s, “Transforming Growth Factor Beta Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Transforming Growth Factor Beta Inhibitors pipeline landscape. It covers the Transforming Growth Factor Beta Inhibitors pipeline drug profiles, including … Continue reading →

Ovarian Cancer Clinical Trial Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Ovarian Cancer Pipeline Insights 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Ovarian Cancer pipeline landscape. It covers the Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

PD-1 and PD-L1 Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook

DelveInsight’s “PD-1 and PD-L1 Inhibitors Competitive landscape 2026” report provides comprehensive insights about 180+ companies and 200+ drugs in the PD-1 and PD-L1 Inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule … Continue reading →